In this weeks podcast from VJOncology, five leading experts share updates and insights on the evolving landscape of precision medicine in sarcoma.

Robin Jones discusses the complexities of implementing precision medicine and presents results from a Phase III trial of catequentinib in advanced leiomyosarcoma. Javier Martín-Broto explores recent advances in immunotherapy and shares findings from Cohort 7A of the ImmunoSarc2 trial, evaluating epirubicin and ifosfamide plus nivolumab in undifferentiated pleomorphic sarcoma. Nadia Hindi highlights Cohort 2, which assessed sunitinib and nivolumab in extraskeletal myxoid chondrosarcoma. Ramya Ramaswami addresses unmet needs in Kaposi sarcoma and presents data from a Phase I trial of efineptakin alfa in patients with and without HIV. Finally, Brian Van Tine discusses a Phase II trial of olaparib and temozolomide in advanced uterine leiomyosarcoma.

The post Sarcoma awareness month: advances in precision medicine appeared first on VJOncology.

In this week’s VJOncology podcast, we have the pleasure to bring you key updates in CAR-T and cellular therapies in brain tumors. Gain expert insights on landmark trials, treatment advances, and shifting screening practices from some of the foremost voices in the field. Topics of discussion include a Phase I trial of intracranial B7H3-directed CAR-T cell therapy in patients with recurrent glioblastoma, effective strategies in anti-glioblastoma CAR-T cells, and dendritic cell therapy in recurrent glioblastoma.

The post CAR-T and cellular therapy updates in brain tumors appeared first on VJOncology.

This week’s VJOncology podcast episode highlights four breakthrough studies from ESMO GI 2025 in Barcelona, Spain, featuring expert insights on gastrointestinal cancer advances. Coverage includes the EXPEL PANC study combining BXCL701 with pembrolizumab for pancreatic cancer, SIERRA study safety data on the STRIDE regimen for hepatocellular carcinoma, TALENTACE trial results combining TACE with atezolizumab plus bevacizumab, and updated MATTERHORN study data on perioperative immunotherapy for gastric cancer. Leading oncologists share perspectives on these game-changing developments reshaping GI cancer treatment live from Barcelona, Spain.

The post Breakthrough advances from ESMO GI 2025 appeared first on VJOncology.

Join esteemed experts Joao Victor Alessi, Hospital Sírio-Libanês, Sao Paolo, Brazil, and Alessandro Di Federico, Dana-Farber Cancer Institute, Boston, MA, as they discuss the most anticipated updates in lung cancer presented at ASCO 2025, as they comment on ground-breaking trials and provide their insights on the significance of the findings and updates.

In this episode, they comment on the potential of new agents like tarlatamab, and pivotal trials such as the OptiTROP-Lung03 trial of sacituzumab tirumotecan in EGFR-mutated non-small cell lung cancer (NSCLC), the CheckMate 816 trial of neoadjuvant nivolumab plus chemotherapy, and the ALNEO trial of alectinib in ALK-positive NSCLC.

The post Lung cancer highlights from ASCO 2025 with Joao Victor Alessi and Alessandro Di Federico appeared first on VJOncology.

Join our experts as they delve into the latest advancements in breast cancer presented at ASCO 2025, as they comment on highly anticipated trials and gives their perspectives on the significance of the findings and updates.

In this episode, Kevin Kalinsky, Emory University Hospital, Atlanta, GA, and Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY, receive updates on trials presented at this year’s ASCO, including the ASCENT-04 trial (NCT05382286) of sacituzumab govitecan and pembrolizumab in PD-L1-positive triple-negative breast cancer (TNBC) and the DESTINY-Breast09 trial (NCT04784715) of first-line trastuzumab deruxtecan (T-DXd) and pertuzumab in patients with HER2+ breast cancer.

The post Breast Cancer highlights from ASCO 2025 with Kevin Kalinsky and Komal Jhaveri appeared first on VJOncology.

In this weeks VJOncology podcast, we have the pleasure to bring you key updates in gynecological cancer from ASCO 2025, which we attended live in Chicago, IL. Join leading experts as they comment on key trials and provide their insights on the ever-evolving treatment landscape and screening patterns.

Dr Jyoti Mayadev gives an overview of highly anticipated trials at the conference including the CALLA, OUTBACK and KEYNOTE-A18 trials, and Dr Shannon Westin discusses findings from the ctDNA findings from the DUO-E trial in endometrial cancer. Dr Kamran Ahmed comments on the efficacy of SBRT followed by atezolizumab in cervical cancer, and Dr Ritu Salani provides results of the TroFuse-020 trial of sacituzumab tirumotecan in pre-treated cervical cancer.

The post Gynecological cancer updates at ASCO 2025 appeared first on VJOncology.

In this ASCO 2025 edition of VJOncology podcasts, we spotlight five game-changing studies set to reshape cancer care across multiple tumor types.

Join our host and a panel of leading oncology experts as they unpack the most impactful data from this year’s American Society of Clinical Oncology Annual Meeting. Discover pivotal insights from the MATTERHORN trial in gastric cancer, explore KRAS G12C-targeted combinations in NSCLC, and delve into resistance-prevention strategies in HR+/HER2– breast cancer with findings from the SERENA-6 trial. We also explore the potential of mRNA-based bispecific antibodies for solid tumors and analyze expanded results from CheckMate 8HW in MSI-high colorectal cancer.

With commentary from top investigators including Yelena Janjigian, Alexander Spira, Michael Gnant, Timothy Yap, and Heinz-Josef Lenz, this episode offers essential updates for oncology professionals. Tune in for a concise, expert-led review of the most practice-changing research from ASCO 2025.

The post Breakthrough advances from ASCO 2025 appeared first on VJOncology.

Welcome to another episode of the VJ Oncology Podcast, where we bring you the forefront of cancer research and clinical practice. This week, we focus on the revolutionary field of cell therapy for solid tumors, with particular emphasis on lung cancer and melanoma, as discussed during the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, held in Miami, FL.

Join Dr. Alison Betoff-Warner and Dr. Ben Creelan as they discuss the potential of targets like TILs, TCRs, and CAR-Ts. Learn about the challenges posed by IL-2 toxicity and discover the latest developments in emerging trials, including promising advancements in therapies targeting PREM and P53.

Don’t miss out on these expert insights into the future of cancer treatment, and explore how innovative cell therapy approaches are transforming the landscape of oncology.

The post Expanding Cell Therapy – TILs, TCRs & CARs in Lung Cancer and Melanoma appeared first on VJOncology.

In this week’s podcast, we take you through the latest episodes of the VJOncoAlert Journal Club—a collaborative series from VJOncology and OncoAlert that brings together leading oncology experts to discuss the most impactful and practice-changing research in the field.

We are joined by Misty Shields, MD, PhD, from the Indiana University Simon Comprehensive Cancer Center in Indianapolis, IN, who discusses the latest updates in small cell lung cancer. Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute in London, UK, and Brian Rini, MD, FASCO, of Vanderbilt-Ingram Cancer Center in Nashville, TN, comment on the health-related quality of life (HRQoL) results from the LITESPARK-005 trial (NCT04195750) in advanced renal cell carcinoma (RCC). Berend J van der Wilk, MD, PhD, from Erasmus MC Cancer Institute in Rotterdam, Netherlands, discusses the SANO trial—a multicenter, non-inferiority, stepped wedge cluster randomized trial investigating active surveillance versus standard resection following neoadjuvant chemoradiotherapy for locally advanced esophageal cancer. Lastly, Luca Arecco, MD, from the University of Genova in Genova, Italy, comments on the prognostic implications of risk definitions from the monarchE (NCT03155997) and NATALEE (NCT03701334) trials.

The post VJOncoAlert Journal Club appeared first on VJOncology.

Welcome to this week’s podcast by VJOncology, where we delve into the latest developments in adjuvant therapy for hepatocellular carcinoma. Join five leading experts as they discuss cutting-edge research and its impact on clinical practices.

Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS Medical School Singapore, Singapore, and Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, break down the latest research, ongoing clinical trials, and what these developments mean for clinical practice. They touch on the promising results of the IMbrave150 and IMbrave050 trial, the Phase II study of regorafenib and pembrolizumab, the KEYSTEP-004 trial and future prospects for these adjuvant therapies.

The post Adjuvant Therapy for Hepatocellular Carcinoma appeared first on VJOncology.